TABLE 3.

Adverse event of special interest post vaccination in the USA

	Venous and arterial thrombotic events	Bell's palsy	Myocarditis/pericarditis	Anaphylaxis	Guillian‐Barre syndrome	Transverse myelitis
Vaccine manufacture
Pfizer/BioNtech
n	2997	2457	1984	1076	307	84
Per million dose	11.43	9.37	7.57	4.1	1.17	0.32
Moderna
n	2338	1856	1056	684	224	67
Per million dose	13.57	10.77	6.13	3.97	1.3	0.39
Johnson & Johnson's Janssen
n	1695	417	134	112	203	26
Per million dose	103.1	25.35	8.15	6.81	12.35	1.58
Sex
Male
n	2845	1949	2186	1504	365	74
%	41.55	41.83	69.91	83.6	51.19	41.57
Female
n	4002	2710	941	295	348	104
%	58.45	58.17	30.1	16.4	48.81	58.43
Age
<18
n	54	36	493	19	11	1
%	0.85	1.93	23.68	6.79	3.25	0.61
18–29
n	336	125	742	41	20	14
%	5.28	6.72	35.64	14.64	5.92	8.54
30–39
n	847	259	322	62	24	31
%	13.31	13.92	15.47	22.14	7.10	18.90
40–49
n	1146	352	172	43	55	27
%	18.01	18.91	8.26	15.36	16.27	16.46
50–59
n	1236	394	139	42	79	28
%	19.42	21.17	6.68	15	23.37	17.07
60–64
n	668	199	55	25	42	18
%	10.5	10.69	2.64	8.93	12.43	10.98
65–79
n	1574	401	140	40	87	37
%	24.74	21.55	6.72	14.29	25.74	22.56
>80
n	502	95	19	8	20	8
%	7.9	5.10	0.91	2.86	5.92	4.88